Detailed information for compound 410085

Basic information

Technical information
  • TDR Targets ID: 410085
  • Name: N-[3-(3-methoxyphenyl)-3-phenylpropyl]acetami de
  • MW: 283.365 | Formula: C18H21NO2
  • H donors: 1 H acceptors: 1 LogP: 3.28 Rotable bonds: 7
    Rule of 5 violations (Lipinski): 1
  • SMILES: COc1cccc(c1)C(c1ccccc1)CCNC(=O)C
  • InChi: 1S/C18H21NO2/c1-14(20)19-12-11-18(15-7-4-3-5-8-15)16-9-6-10-17(13-16)21-2/h3-10,13,18H,11-12H2,1-2H3,(H,19,20)
  • InChiKey: OJTOLFDTLADRFL-UHFFFAOYSA-N  


Substructure search Similarity search

Network

Hover on a compound node to display the structore

Synonyms

  • N-[3-(3-methoxyphenyl)-3-phenyl-propyl]acetamide
  • N-[3-(3-methoxyphenyl)-3-phenyl-propyl]ethanamide

Targets

Known targets for this compound

Species Target name Source Bibliographic reference
Homo sapiens melatonin receptor 1B Starlite/ChEMBL References
Homo sapiens melatonin receptor 1A Starlite/ChEMBL References

Predicted pathogen targets for this compound

By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
Species Potential target Known druggable target Length Alignment span Identity
Brugia malayi hypothetical protein melatonin receptor 1B 362 aa 329 aa 18.8 %
Obtained from network model

Ranking Plot

Putative Targets List

Species Potential target Raw Global Species
Leishmania major 0.1293 1 0.5
Schistosoma mansoni fructose-16-bisphosphatase-related 0.1293 1 0.5
Trypanosoma cruzi fructose-1,6-bisphosphatase, cytosolic, putative 0.1293 1 1
Toxoplasma gondii fructose-bisphospatase II 0.1293 1 1
Trypanosoma cruzi fructose-1,6-bisphosphatase, cytosolic, putative 0.1293 1 1
Loa Loa (eye worm) fructose-1,6-bisphosphatase 0.1293 1 0.5
Trypanosoma brucei fructose-1,6-bisphosphatase 0.1293 1 1
Echinococcus granulosus fructose 16 bisphosphatase 1 0.1293 1 0.5
Echinococcus multilocularis fructose 1,6 bisphosphatase 1 0.1293 1 0.5

Activities

Activity type Activity value Assay description Source Reference
Intrinsic activity (functional) = 0.04 Intrinsic activity at human MT2 receptor expressed in NIH3T3 cells assessed as stimulation of [35S]GTPgammaS binding relative to MLT ChEMBL. 17149869
Intrinsic activity (functional) = 0.24 Intrinsic activity at human MT1 receptor expressed in NIH3T3 cells assessed as stimulation of [35S]GTPgammaS binding relative to MLT ChEMBL. 17149869
Intrinsic activity (functional) = 0.04 Intrinsic activity at human MT2 receptor expressed in NIH3T3 cells assessed as stimulation of [35S]GTPgammaS binding relative to MLT ChEMBL. 17149869
Intrinsic activity (functional) = 0.24 Intrinsic activity at human MT1 receptor expressed in NIH3T3 cells assessed as stimulation of [35S]GTPgammaS binding relative to MLT ChEMBL. 17149869
Ki (binding) = -8.27 Displacement of 2-[125I]melatonin from human MT2 receptor expressed in NIH3T3 cells ChEMBL. 17149869
Ki (binding) = -5.66 Displacement of 2-[125I]melatonin from human MT1 receptor expressed in NIH3T3 cells ChEMBL. 17149869
Log Ki (binding) = 5.66 Displacement of 2-[125I]melatonin from human MT1 receptor expressed in NIH3T3 cells ChEMBL. 17149869
Log Ki (binding) = 8.27 Displacement of 2-[125I]melatonin from human MT2 receptor expressed in NIH3T3 cells ChEMBL. 17149869
Selectivity ratio (binding) > 2 Selectivity for human MT2 receptor over MT1 receptor ChEMBL. 17149869
Selectivity ratio (binding) > 2 Selectivity for human MT2 receptor over MT1 receptor ChEMBL. 17149869

Phenotypes

Whole-cell/tissue/organism interactions

We have no records of whole-cell/tissue assays done with this compound What does this mean?

Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.

Annotated phenotypes:

We have no manually annotated phenotypes for this drug. What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by drugs, or by genetic manipulation of cells (e.g. gene knockouts or knockdowns) is manually curated from the literature. These descriptions help to describe the potential of the target for drug development. If no information is available for this gene or if the information is incomplete, this may mean that i) the papers containing this information either appeared after the curation effort for this organism was carried out or they were inadvertently missed by curators; or that ii) the curation effort for this organism has not yet started.
 
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.

External resources for this compound

Bibliographic References

1 literature reference was collected for this gene.

If you have references for this compound, please enter them in a user comment (below) or Contact us.